# DESCRIPTION

## FIELD OF THE INVENTION

- relate to biomarkers for predicting clinical response of VEGF-A inhibitory drug

## BACKGROUND

- introduce anti-angiogenic treatment
- discuss importance of VEGF-A in cancer cell growth and metastasis
- summarize limitations of current biomarkers

## SUMMARY

- define present invention
- outline in vitro method for predicting response to VEGF-A inhibitory drug
- describe method for treatment of solid malignant tumor
- introduce kit for use in method

## DETAILED DESCRIPTION

- define method for predicting response to VEGF-A inhibitory drug
- introduce solid malignant tumor samples and gene expression analysis
- describe mRNA quantification methods
- describe protein quantification methods
- explain normalization of expression levels
- introduce ViRP-score calculation and its use in predicting response
- discuss treatment strategies based on ViRP-score
- describe advantages of the method
- provide examples of using the method

### Treatment Regimen

- describe treatment regimens using VEGF-A-inhibitory drug

### Relative Importance of Proteins and Modelling of Protein Combinations

- discuss relative importance of proteins and modeling of protein combinations

## EXAMPLES

- illustrate identification of ten protein prognostic signature

### Example 1: Identification of Ten Protein Prognostic Signature

- describe patient cohort
- explain sample processing and protein expression profiling
- detail statistical analysis and signature development
- develop predictive protein signature score
- evaluate predictive performance of ViRP-scores
- discuss potential clinical benefit of using ViRP-score

